Cargando…

Behavioral Activation Therapy for Subthreshold Depression in Stroke Patients: An Exploratory Randomized Controlled Trial

BACKGROUND: Subthreshold depression (SD) is known to be a major risk factor for the development of post-stroke depression (PSD). Appropriate intervention to prevent the transition from SD to PSD is thus imperative. As a form of short-term psychotherapy adapted for individuals with cognitive and comm...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Qiuxue, Xu, Hailian, Zhang, Wenyue, Zhou, Yuqiu, Lv, Yumei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719268/
https://www.ncbi.nlm.nih.gov/pubmed/36471746
http://dx.doi.org/10.2147/NDT.S392403
_version_ 1784843284262158336
author Sun, Qiuxue
Xu, Hailian
Zhang, Wenyue
Zhou, Yuqiu
Lv, Yumei
author_facet Sun, Qiuxue
Xu, Hailian
Zhang, Wenyue
Zhou, Yuqiu
Lv, Yumei
author_sort Sun, Qiuxue
collection PubMed
description BACKGROUND: Subthreshold depression (SD) is known to be a major risk factor for the development of post-stroke depression (PSD). Appropriate intervention to prevent the transition from SD to PSD is thus imperative. As a form of short-term psychotherapy adapted for individuals with cognitive and communication impairments, behavioral activation therapy (BAT) may be a suitable choice. However, the effects of BAT on psychological outcomes in stroke patients with SD has not been established. This study investigated the feasibility and effectiveness of BAT in reducing the development of depressive symptoms in this patient population. METHODS: A double-blind, randomized controlled trial was performed. Seventy participants were randomized to either a BAT group (n=35) or a control group (n=35). Participants in the BAT group received a six-week BAT intervention. The feasibility of BAT was assessed by the number of sessions attended by participants, and the acceptability of BAT to participants and the incidence of adverse events were recorded. The primary clinical outcome measure was the Center for Epidemiological Studies Depression Scale (CES-D) and the 17-item Hamilton Depression Scale (HAMD-17) at baseline, six weeks, and three months after the group allocation. Secondary outcomes included behavioral activation and the incidence of depression. RESULTS: The intervention was feasible and acceptable, with 94.3% of participants in the BAT group (33 of 35) attending at least five sessions. No adverse events were reported in either group. Compared with the control group, the BAT group showed significant improvements in the CES-D (F=67.689, P<0.05), HAMD-17 (F=4.170, P<0.05), and behavioral activation (F=25.355, P<0.05) scores after intervention, and these differences were maintained at the three-month assessment. CONCLUSION: BAT appears to be feasible and efficacious for reducing depressive symptoms and increasing behavioral activation among stroke patients with SD. The findings of this study may contribute to the primary prevention of PSD.
format Online
Article
Text
id pubmed-9719268
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97192682022-12-04 Behavioral Activation Therapy for Subthreshold Depression in Stroke Patients: An Exploratory Randomized Controlled Trial Sun, Qiuxue Xu, Hailian Zhang, Wenyue Zhou, Yuqiu Lv, Yumei Neuropsychiatr Dis Treat Clinical Trial Report BACKGROUND: Subthreshold depression (SD) is known to be a major risk factor for the development of post-stroke depression (PSD). Appropriate intervention to prevent the transition from SD to PSD is thus imperative. As a form of short-term psychotherapy adapted for individuals with cognitive and communication impairments, behavioral activation therapy (BAT) may be a suitable choice. However, the effects of BAT on psychological outcomes in stroke patients with SD has not been established. This study investigated the feasibility and effectiveness of BAT in reducing the development of depressive symptoms in this patient population. METHODS: A double-blind, randomized controlled trial was performed. Seventy participants were randomized to either a BAT group (n=35) or a control group (n=35). Participants in the BAT group received a six-week BAT intervention. The feasibility of BAT was assessed by the number of sessions attended by participants, and the acceptability of BAT to participants and the incidence of adverse events were recorded. The primary clinical outcome measure was the Center for Epidemiological Studies Depression Scale (CES-D) and the 17-item Hamilton Depression Scale (HAMD-17) at baseline, six weeks, and three months after the group allocation. Secondary outcomes included behavioral activation and the incidence of depression. RESULTS: The intervention was feasible and acceptable, with 94.3% of participants in the BAT group (33 of 35) attending at least five sessions. No adverse events were reported in either group. Compared with the control group, the BAT group showed significant improvements in the CES-D (F=67.689, P<0.05), HAMD-17 (F=4.170, P<0.05), and behavioral activation (F=25.355, P<0.05) scores after intervention, and these differences were maintained at the three-month assessment. CONCLUSION: BAT appears to be feasible and efficacious for reducing depressive symptoms and increasing behavioral activation among stroke patients with SD. The findings of this study may contribute to the primary prevention of PSD. Dove 2022-11-29 /pmc/articles/PMC9719268/ /pubmed/36471746 http://dx.doi.org/10.2147/NDT.S392403 Text en © 2022 Sun et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Clinical Trial Report
Sun, Qiuxue
Xu, Hailian
Zhang, Wenyue
Zhou, Yuqiu
Lv, Yumei
Behavioral Activation Therapy for Subthreshold Depression in Stroke Patients: An Exploratory Randomized Controlled Trial
title Behavioral Activation Therapy for Subthreshold Depression in Stroke Patients: An Exploratory Randomized Controlled Trial
title_full Behavioral Activation Therapy for Subthreshold Depression in Stroke Patients: An Exploratory Randomized Controlled Trial
title_fullStr Behavioral Activation Therapy for Subthreshold Depression in Stroke Patients: An Exploratory Randomized Controlled Trial
title_full_unstemmed Behavioral Activation Therapy for Subthreshold Depression in Stroke Patients: An Exploratory Randomized Controlled Trial
title_short Behavioral Activation Therapy for Subthreshold Depression in Stroke Patients: An Exploratory Randomized Controlled Trial
title_sort behavioral activation therapy for subthreshold depression in stroke patients: an exploratory randomized controlled trial
topic Clinical Trial Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719268/
https://www.ncbi.nlm.nih.gov/pubmed/36471746
http://dx.doi.org/10.2147/NDT.S392403
work_keys_str_mv AT sunqiuxue behavioralactivationtherapyforsubthresholddepressioninstrokepatientsanexploratoryrandomizedcontrolledtrial
AT xuhailian behavioralactivationtherapyforsubthresholddepressioninstrokepatientsanexploratoryrandomizedcontrolledtrial
AT zhangwenyue behavioralactivationtherapyforsubthresholddepressioninstrokepatientsanexploratoryrandomizedcontrolledtrial
AT zhouyuqiu behavioralactivationtherapyforsubthresholddepressioninstrokepatientsanexploratoryrandomizedcontrolledtrial
AT lvyumei behavioralactivationtherapyforsubthresholddepressioninstrokepatientsanexploratoryrandomizedcontrolledtrial